Adenosine A 2A receptor (A 2A R)-dopamine D 2 receptor (D 2 R) heteromers are key modulators of striatal neuronal function. It has been suggested that the psychostimulant effects of caffeine depend on its ability to block an allosteric modulation within the A 2A R-D 2 R heteromer, by which adenosine decreases the affinity and intrinsic efficacy of dopamine at the D 2 R. We describe novel unsuspected allosteric mechanisms within the heteromer by which not only A 2A R agonists, but also A 2A R antagonists, decrease the affinity and intrinsic efficacy of D 2 R agonists and the affinity of D 2 R antagonists. Strikingly, these allosteric modulations disappear on agonist and antagonist coadministration. This can be explained by a model that considers A 2A R-D 2 R heteromers as heterotetramers, constituted by A 2A R and D 2 R homodimers, as demonstrated by experiments with bioluminescence resonance energy transfer and bimolecular fluorescence and bioluminescence com- 
M ost evidence indicates that G protein-coupled receptors (GPCRs) form homodimers and heteromers. Homodimers seem to be a predominant species, and oligomeric entities can be viewed as multiples of dimers (1) . It has been proposed that GPCR heteromers are constituted mainly by heteromers of homodimers (1, 2) . Allosteric mechanisms determine a multiplicity of unique pharmacologic properties of GPCR homodimers and heteromers (1, 3) . First, binding of a ligand to one of the receptors in the heteromer can modify the affinity of ligands for the other receptor (1, 3, 4) . The most widely reproduced allosteric modulation of ligand-binding properties in a GPCR heteromer is the ability of adenosine A 2A receptor (A 2A R) agonists to decrease the affinity of dopamine D 2 receptor (D 2 R) agonists in the A 2A R-D 2 R heteromer (5) . A 2A R-D 2 R heteromers have been revealed both in transfected cells (6, 7) , striatal neurons in culture (6, 8) and in situ, in mammalian striatum (9, 10) , where they play an important role in the modulation of GABAergic striatopallidal neuronal function (9, 11) .
In addition to ligand-binding properties, unique properties for each GPCR oligomer emerge in relation to the varying intrinsic efficacy of ligands for different signaling pathways (1) (2) (3) . Intrinsic efficacy refers to the power of the agonist to induce a functional response, independent of its affinity for the receptor. Thus, allosteric modulation of an agonist can potentially involve changes in affinity and/or intrinsic efficacy (1, 3) . This principle can be observed in the A 2A R-D 2 R heteromer, where a decrease in D 2 R agonist affinity cannot alone explain the ability of an A 2A R agonist to abolish the decreased excitability of GABAergic striatopallidal neurons induced by high concentration of a D 2 R agonist (9) , which should overcome the decrease in affinity. Furthermore, a differential effect of allosteric modulations of different agonist-mediated signaling responses (i.e., functional selectivity) can occur within GPCR heteromers (1, 2, 8) . Again, the A 2A R-D 2 R heteromer provides a valuable example. A recent study has shown that different levels of intracellular Ca 2+ exert different modulations of A 2A R-D 2 R heteromer signaling (8) . This depends on the ability of low and high Ca 2+ to promote a selective interaction of the heteromer with different Ca 2+ -binding proteins, which differentially modulate allosteric interactions in the heteromer (8) .
It has been hypothesized that the allosteric interactions between A 2A R and D 2 R agonists within the A 2A R-D 2 R heteromer provide a mechanism responsible not only for the depressant effects of A 2A R agonists, but also for the psychostimulant effects of adenosine A 2A R antagonists and the nonselective adenosine receptor antagonist caffeine (9, 11, 12) , with implications for several neuropsychiatric disorders (13) . In fact, the same mechanism has provided the rationale for the use of A 2A R antagonists Significance G protein-coupled receptors (GPCRs) constitute the largest plasma membrane protein family involved in cell signaling. GPCR homodimers are predominant species, and GPCR het- in patients with Parkinson's disease (13, 14) . The initial aim of the present study was to study in detail the ability of caffeine to counteract allosteric modulations between A 2A R and D 2 R agonists (affinity and intrinsic efficacy) within the A 2A R-D 2 R heteromer. Unexpectedly, when performing control radioligandbinding experiments, not only an A 2A R agonist, but also caffeine, significantly decreased D 2 R agonist binding. However, when coadministered, the A 2A R agonist and caffeine co-counteracted their ability to modulate D 2 R agonist binding. By exploring the molecular mechanisms behind these apparent inconsistencies, the present study provides new insight into the quaternary structure and function of A 2A R-D 2 R heteromers. (Fig. 1A, red bars) . Unexpectedly, caffeine also produced the same effect (Fig. 1B) (Fig. 3) , indicating formation of a hybrid species with both agonist and antagonist simultaneously binding to the dimer. Therefore, only the agonist can exert an allosteric modulation of the labeled antagonist when both are occupying orthosteric sites in an A 2A R oligomer, because the four ligands-caffeine, ZM 241385, SCH 58261, and CGS 21680-all bind and compete for the same orthosteric site (19) (20) (21) . This implies a different conformation of the A 2A R homodimer when occupied simultaneously with an agonist and an antagonist compared with when occupied with two antagonists. This different conformation could then explain the differential ability of the A 2A R homodimer, when occupied only by an agonist or an antagonist or simultaneously by an agonist and antagonist, to allosterically modulate D 2 R agonist binding and intrinsic efficacy within the A 2A R-D 2 R heteromer.
Results
The same allosteric modulation exerted by A 2A R agonists and antagonists on D 2 R agonist affinity was also evident on The effect of quinpirole was partially but significantly counteracted by CGS 21680 to the levels of ERK1/2 phosphorylation induced by CGS 21680 alone. Given that the high concentration of quinpirole used (1 μM) should overcome the decrease in affinity induced by CGS 21680 (100 nM) (Table 1) , this indicates the ability of the A 2A R agonist to decrease not only D 2 R agonist affinity, but also its intrinsic efficacy, as previously shown in electrophysiological experiments on striatal neurons (9) . Increasing concentrations of caffeine (Fig. 2B ), SCH 58261 ( Fig. 2D ), or KW 6002 (Fig. 2F) (Fig. 4A) . A 1 R-D 2 R and A 2A R-D 1 R pairs (fused to corresponding hemiproteins) served as negative controls here as well (Fig. 4A) .
Finally, complemented Rluc from A 2A R(nRluc)-D 2 R(cRluc) heteromers and complemented YFP from A 2A R(nYFP)-D 2 R (cYFP) heteromers were used as donor and acceptor molecules in bioluminescence resonance energy transfer (BRET) experiments (Fig. 4B ). Significant BRET values were obtained with cotransfection of A 2A R-nRluc, D 2 R-cRluc, A 2A R-nYFP, and D 2 R-cYFP (Fig. 4B) . A 1 R-D 2 R and A 2A R-D 1 R pairs (fused to corresponding hemiproteins) again served as negative controls (Fig. 4B) . Further controls included independent experiments replacing each receptor fused to its hemiprotein with the same nonfused (soluble) hemiprotein (Table S1 ).
Bimolecular fluorescence complementation was also used to evaluate the ability of peptides with the amino acid sequence of transmembrane domains (TMs) to destabilize A 2A R-D 2 R heteromers, as recently described for dopamine D 1 R-D 3 R heteromers (2) . Previous BRET experiments with disrupting peptides had suggested the involvement of TM5 from D 2 R in A 2A R-D 2 R heteromerization (18) . We investigated whether synthetic peptides with the sequence of TM5 and TM7 of A 2A R or D 2 R fused to HIV TAT were able to destabilize receptor heteromerization. Both TM5 peptides, but none of the TM7 peptides, reduced fluorescence complementation in cells expressing A 2A R-nYFP and D 2 R-cYFP (Fig. 4A) , suggesting that, in addition to intracellular domains, TM5 forms part of the heteromerization interface. In contrast, neither TM5 or TM7 from A 2A R or D 2 R was able to decrease fluorescence complementation in cells expressing A 2A R-nYFP and A 2A R-cYFP or D 2 R-nYFP and D 2 R-cYFP (Fig. 4A) , supporting the selective involvement of TM5 on the heteromer interface. (9) . It was also shown that SCH 58261 counteracts the allosteric effect of CGS 21680 on D 2 R function (9), but the effect of the A 2A R antagonist alone was not analyzed. Under these experimental conditions, the slice bathing solution is free of endogenous neurotransmitters, thereby allowing testing in situ of the A 2A R agonist/antagonist-mediated allosteric modulation of D 2 R function without the interference of endogenous adenosine. We first reproduced the effect of NMDA (5 μM; increase in neuronal firing) and the counteraction of this effect by the D 2 R agonist agonist R(−)-propylnorapomorphine hydrochloride (NPA; 10 μM) (Fig. 5A) . Remarkably, the A 2A R antagonist SCH 58261 (1 μM) completely counteracted the effect of the D 2 R agonist ( Fig. 5 A and B) , as reported for CGS 21680. These results mirror those obtained with transfected cells and demonstrate that both A 2A R agonists and antagonists are able to modulate D 2 R function in the striatum. It is well known that locomotor activation by A 2A R antagonists or caffeine shows an inverted U-shaped dose-response curve, with a depressant effect at high doses (23) (24) (25) . This depressant effect could be related to the ability of the antagonists to largely displace endogenous adenosine and occupy both protomers in the A 2A R homodimer of the A 2A R-D 2 R hetero- mer. In that case, we would predict that coadministration of a depressant dose of an A 2A R agonist should not produce more depression, but rather should counteract the depressant effect of the antagonists. We tested locomotor activity in rats during the first 20 min of activity of nonhabituated animals with doses of the A 2A R antagonist KW 6002 above 1 mg/kg, reportedly the maximal effective dose (23) . KW 6002 also produced a biphasic effect on D 2 R binding and MAPK signaling (Fig. 2F) , and it was selected because of its pronounced locomotor effects compared with SCH 58261 (23) . At 10 mg/kg, KW 6002 did not produce any activation, and at 30 mg/kg it had a depressant effect (Fig. 5C ). As predicted, coadministration of a depressant dose of CGS 21680 (0.1 mg/kg) (24) counteracted the depressant effect of KW 6002 (30 mg/kg) (Fig. 5C) . The same dose of CGS 21680 did not significantly counteract (although it did not potentiate) the motor depressant effects of high doses of caffeine (56 and 100 mg/kg) (Fig. S3) . Thus, these results agree with previous studies indicating that mechanisms other than adenosine receptor antagonism are involved in the depressant effects of high doses of caffeine (25 (Fig. 6 A and B) 3 H]raclopride-specific binding (% of nontreated membranes). Statistical significance was calculated by one-way ANOVA followed by Dunnett's post hoc test or the Newman-Keuls post hoc test. *P < 0.05; **P < 0.01; ***P < 0.001, compared with the untreated membrane preparations.
# P < 0.05; ## P < 0.01, compared with the membranes treated only with CGS 21680. controls of adenosine receptor selectivity, neither the A 1 R agonist CCPA nor the A 1 R antagonist DPCPX modulated [ 3 H] raclopride binding at concentrations that do not bind to A 2A R (Fig. S4) . Again, the potency of both CGS 21680 and caffeine in modulating [ 3 H]raclopride binding was significantly reduced in cells expressing the mutant A 2A A374 R, indicating dependence on A 2A R-D 2 R heteromerization (Fig. 6 A and B) . In fact, the same reduction in the potency of CGS 21680 and caffeine observed in cells expressing the mutant A 2A A374 R was observed in cells transfected only with D 2 R (Fig. 6 A and B (Fig. 6C) .
We then used disrupting TM peptides to demonstrate that heteromerization is involved in the A 2A R ligand-mediated modulation of D 2 R binding in striatal tissue. We first checked endogenous A 2A R-D 2 R heteromer expression in sheep striatal slices by a proximity ligation assay (PLA). This technique permits the detection of molecular interactions between two endogenous proteins and it is similar to immunoprecipitation, but with the additional advantage of not requiring membrane solubilization. Labeling heterodimers by PLA requires that both receptors be sufficiently close to allow the two antibody-DNA probes to form double-stranded segments (<16 nm) (10), a signal that is further amplified in the presence of fluorescent nucleotides (Fig. 7) . On the PLA, A 2A R-D 2 R heteromers were observed as red punctate staining in slices treated with vehicle or with TM7 peptides, but not in slices treated with TM5 peptides from A 2A R or D 2 R (Fig. 7 C and E) . Because TM5 peptides disrupted both fluorescence complementation (Fig.  3A) and the PLA signal (Fig. 7) , we expected that this alteration of the quaternary structure should result in the loss of the allosteric interactions within the heteromer. Indeed, TM5 peptides from both A 2A R (Fig. 8A) and D 2 R (Fig. 8B) , but not TM7 peptides, counteracted caffeine-mediated decrease in [ 3 H]raclopride binding in sheep striatal membrane preparations (Fig. 8) .
Discussion
Several conclusions can be drawn from this study. First, any orthosteric A 2A R ligand, agonist or antagonist, can decrease the affinity and intrinsic efficacy of any D 2 R ligand. These features constitute biochemical properties of the A 2A R-D 2 R heteromer, because they depend on the integrity of the right quaternary structure of the heteromer, as demonstrated in transfected mammalian cells and striatal tissue, by using heteromer-disrupting mutations and peptides, respectively. Second, the results from radioligand dissociation and double complementation of BRET donor and acceptor units provide strong evidence for a tetrameric structure of the A 2A R-D 2 R heteromer constituted by A 2A R and D 2 R homodimers. Third, the A 2A R-D 2 R heterotetramer offers a model that explains the apparent contradiction of orthosteric A 2A R agonists and antagonists being able to produce the same modulatory effects on D 2 R function and yet counteract each other's effects. The model assumes that occupancy of the A 2A R homodimer with either an agonist or an antagonist produces a conformational change that conduces the same allosteric modulation to the D 2 R, whereas simultaneous occupancy of the A 2A R homodimer by an agonist and an antagonist would not allow this conformational change (as indicated by dissociation experiments with the radiolabeled A 2A R antagonist).
The model has important heuristic value. As the model predicted, in the brain, under specific pharmacologic conditions, orthosteric A 2A R antagonists behave as A 2A R agonists and decrease D 2 R function, effects that can be counteracted by coadministration of both A 2A R agonists and antagonists (electrophysiological and locomotor activity experiments). Given the tone of adenosine under physiological conditions, this in fact could be the main mechanism by which caffeine and A 2A R antagonists produce locomotor activation, by counteracting the functional effects that depend on D 2 R signaling by the A 2A R-D 2 R heteromer. Nevertheless, motor depression by caffeine or A 2A R antagonists implies a significant displacement of endogenous adenosine and occupancy of the A 2A R homodimer in the A 2A R-D 2 R heteromer, which can be attained only by high concentrations of caffeine that cannot be obtained through habitual consumption of coffee. Thus, a 12-oz cup of coffee may contain between 107 and 420 mg of caffeine (26), and oral doses of 250 and 500 mg (human adults) produce peak plasma levels of approximately 0.03 and 0.06 mM (27) , which is in the range of concentrations at which caffeine counteracts the allosteric effects of CGS 21680 in the present radioligand-binding experiments ( Figs. 2A and 6C ). However, therapeutic doses of more potent and selective A 2A R antagonists may have differential effects depending on their A 2A R affinity and on the levels of endogenous adenosine. Therefore, our model still provides support for the use of A 2A R antagonists in treating patients with Parkinson's disease. In addition, the complementing results obtained from functional experiments in mammalian cells in culture, in striatal slices, and in the intact experimental animal provide a basis for understanding the previously claimed significant dependence of D 2 R signaling and A 2A R-D 2 R heteromerization on the pharmacologic effects of caffeine and other A 2A R ligands (9, (11) (12) (13) .
Finally, the present results indicate that a large proportion of D 2 R forms heteromers with A 2A R in transfected cells and striatal tissue. A similar degree of allosteric modulation of D 2 R by A 2A R ligands was observed in both artificial and native systems. Particularly notorious was the ability of caffeine to allosterically (noncompetitively) decrease D 2 R antagonist binding by approximately 60% and 40% in membrane preparations of transfected cells and striatal tissue, respectively. Furthermore, the experiments with MAPK signaling in transfected cells and the electrophysiological experiments in striatal neurons demonstrate an additional strong allosteric modulation of A 2A R ligands on the intrinsic efficacy of D 2 R ligands, which can explain, for instance, the complete counteraction by A 2A R antagonists on MAPK activation and the decrease in neuronal excitability induced by high concentrations of D 2 R agonists, which should surmount the reduction in affinity.
More generally, our study calls for an awareness of homodimers as predominant GPCR species, providing a significant role of allosteric interactions between orthosteric ligands within GPCRs and building blocks for heterotetramers (28) , which should have important implications in the field of GPCR pharmacology.
Methods
Animals. Male Sprague-Dawley rats (Charles River Laboratories) weighting 300-350 g were used for all experiments. All animals were handled in accordance with the National Institutes of Health's animal care guidelines. The animal research protocol followed for this study (09-BNRB-73) was approved by the National Institute on Drug Abuse Intramural Research Program's Animal Care and Use Committee. Human Samples. Human brain samples from the nucleus caudate (head area) were obtained by family consent at autopsy in the Basque Institute of Legal Medicine (University of the Basque Country, Bilbao, Spain) from four male subjects without history of neurological or psychiatric disorders and who died suddenly of a car accident. Toxicological screening was negative for all subjects and brain samples were histologically determined as normal. Samples were dissected at the time of autopsy, stored at −70°C until assay and encoded in order to protect the identity of the subject. The time interval between death and autopsy (postmortem delay at 4°C) was 26 ± 4 h. Because HIV TAT binds to the phosphatidylinositol-(4, 5)-bisphosphate found on the inner surface of the membrane, HIV TAT peptide was fused to the C terminus of TM5 and TM7 to obtain the right orientation of the inserted peptide (2).
Fusion Proteins and Expression
Cell Culture and Transient Transfection. CHO and human embryonic kidney (HEK-293) cells were grown in Minimum Essential Medium (MEMα; Gibco) and DMEM (Gibco), respectively, supplemented with 2 mM L-glutamine, 100 μg/mL sodium pyruvate, MEM nonessential amino acid solution (1/100), 100 U/mL penicillin/streptomycin, and 5% (vol/vol) of heat-inactivated FBS (all supplements from Invitrogen). CHO and HEK-293 cells growing in 25-cm 2 flasks or 150-cm 2 dishes were transiently transfected by the polyethilenimine (PEI) method. In brief, cells were incubated for 4 h with the indicated amount of cDNA together with ramified PEI (Sigma-Aldrich; 5 mL of 10 mM PEI for each μg of cDNA) and 150 mM NaCl in a serum-starved medium. After 4 h, the medium was changed to a fresh complete culture medium. Cells were used at 48 h after transfection. ERK1/2 Phosphorylation Assays. The effect of different ligand combinations on ERK1/2 phosphorylation was studied in HEK-293 cells transfected with A 2A R and D 2 R. The methodology is described in detail elsewhere (2) .
BRET and Bimolecular Bioluminescence and Fluorescence Complementation. HEK-293 cells growing in six-well plates were transiently cotransfected with 1 μg of cDNA encoding for the receptors fused to nRLuc8 and cRLuc8 proteins and with 1 μg of cDNA corresponding to the receptors fused to nVenus and cVenus proteins. To quantify receptor-reconstituted YFP Venus expression, cells (20 μg of total protein per well) were distributed in 96-well microplates (black plates with a transparent bottom), and fluorescence was read in a FLUOstar Optima fluorimeter (BMG Labtech). Receptor fluorescence expression was determined as fluorescence of the sample minus the fluorescence of cells expressing the BRET donor alone. For BRET with bimolecular bioluminescence and fluorescence complementation measurements, cells (10 μg of total protein per well) were distributed in 96-well microplates (Corning 3600 white plates), and 5 μM coelenterazine H (Molecular Probes) was added. At 5 min after the addition of coelenterazine H, the readings were collected using a Mithras LB 940 microplate reader (Berthold Technologies), which allows integration of the signals detected in the short-wavelength filter at 485 nm (440-500 nm) and the long-wavelength filter at 530 nm (510-590 nm). To quantify receptor-reconstituted RLuc8 expression, luminescence readings were also performed at 10 min after the addition of 5 mM coelenterazine H. Both the fluorescence and luminescence of each sample were measured before each experiment to confirm similar donor expression (∼150,000 luminescent units). Net BRET was defined as [(long-wavelength emission)/(short-wavelength emission)] − Cf, where Cf corresponds to [(long-wavelength emission)/(shortwavelength emission)] for the donor construct expressed alone in the same experiment. BRET is expressed as mili BRET units (mBU; net BRET × 1,000).
Radioligand-Binding Experiments. Crude membranes from sheep or human striatum (caudate) or cultured CHO cells were prepared as described elsewhere (23 H]raclopride (4 nM) and increasing concentrations of quinpirole (0.01 nM-3 μM) or raclopride (0.01 nM-3 μM), respectively, in the presence or absence of caffeine (3 mM) or CGS 21680 (3 μM). In all cases, free and membrane-bound ligands were separated by rapid filtration, and radioactivity counts were determined as described elsewhere (23) .
Two-state dimer model equations were used to determine radioligandbinding parameters, as described in detail elsewhere (29) . In dissociation kinetic assays, sheep striatal membranes (0.2 mg of protein/mL) were incubated at 12°C in Tris·HCl buffer (50 mM, pH 7.4) containing 10 mM MgCl 2 and 0.2 IU/mL adenosine deaminase in the absence or presence of CGS 21680 (10 nM), SCH 58261 (10 nM), or caffeine (30 μM). After 30 min, 1.5 nM of the A 2A R antagonist [ 3 H]ZM 241385 (50 Ci/mmol; American Radiolabeled Chemicals) was added for an additional 2-h period of radioligand association. Dissociation was initiated by the addition of 10 μM of ZM 241385. At the indicated time intervals, total binding was measured as described above.
Patch-Clamp Recording. Whole-cell patch-clamp recordings were performed on individual neurons from the rat ventral striatum. The method is described in detail elsewhere (9) .
Locomotor Activity. Rats received an i.p. injection of 0.1 mg/kg CGS 21680 or vehicle (saline plus 5% DMSO and 5% Tween-80). After 30 min, they received a second i.p. injection of KW 6002 (1, 10, or 30 mg/kg) or vehicle, and locomotor activity was measured by placing the animals individually in motility chambers (50 × 50 cm; Coulbourn Instruments). Locomotion was measured by counting the number of breaks in the infrared beams of the chambers for the first 20 min after the last i.p. injection.
Proximity Ligation Assay. Sheep striatum placed in ice-cold oxygenated (95% O 2 /5% CO 2 ) Krebs-HCO 3 − buffer (124 mM NaCl, 4 mM KCl, 1.25 mM KH 2 PO 4 , 1.5 mM MgCl 2 , 1.5 mM CaCl 2 , 10 mM glucose, and 26 mM NaHCO 3 ; pH 7.4) were dissected and sliced at 4°C using a brain matrix to obtain 0.5-mm coronal slices. Each slice was transferred to a plate and incubated for 4 h at 30°C under constant oxygenation in an Eppendorf Thermomixer (5 Primer Inc.) with Krebs-HCO 3 − buffer containing or not containing 4 μM of the indicated HIV TAT TM peptides. Slices were fixed with 4% paraformaldehyde solution for 1 h at room temperature, washed in Tris-buffered saline, and stored at −20°C in a 30% sucrose solution until sectioning. The 20-μm-thick coronal sections were cut on a freezing cryostat (Leica Jung CM-3000), mounted on glass slides, and permeabilized for 10 min at 4°C with 0.1% Triton X-100. A 2A R-D 2 R complexes were detected using the Duolink II PLA detection kit (OLink Bioscience) following the manufacturer's instructions using a mixture containing equal amounts of rabbit polyclonal anti-D 2 R antibody (1:200, AB5084P; Millipore) and monoclonal mouse anti-A 2A R antibody (1:200, 05-717; Millipore). The samples were mounted and observed under a Leica SP2 confocal microscope and processed with ImageJ software. Cells containing one or more spots vs. total cells were determined considering 800-1,000 cells from between five and 12 different fields from three different animals per group using the Fiji package (pacific.mpi-cbg.de) as described previously (30) .
